<DOC>
	<DOCNO>NCT00820222</DOCNO>
	<brief_summary>This open label study design evaluate Lapatinib effect incidence brain metastasis ErbB2 ( HER2 ) positive metastatic breast cancer patient expose prior taxanes anthracyclines .</brief_summary>
	<brief_title>Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine ErbB2 ( HER2 ) Positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Females least 18 year old ; ECOG Performance Status 02 ; Histologically cytologically confirm HER2positive invasive breast cancer , Stage IV disease ; Prior treatment taxanes anthracyclines require ; Prior treatment chemotherapeutic agent , trastuzumab , endocrine radiation therapy permit ; Baseline LVEF â‰¥ 50 % low institutional low limit normal ; Concurrent treatment bisphosphonates permit , however treatment must initiate prior first dose study therapy ; Able swallow retain oral medication ; Women potential child must willing practice acceptable method birth control study ; Normal organ marrow function . History and/or current evidence CNS metastasis . Baseline MRI scan Independent Reviewer confirm brain mets ; Concurrent treatment investigational agent participation another treatment clinical trial ; Prior therapy lapatinib ErbB2 inhibitor trastuzumab ( include limit trastuzumabDM1 neratinib ) capecitabine ; Known DPD deficiency ; Concurrent chemotherapy , radiation therapy , immunotherapy , biologic therapy , hormonal therapy treatment cancer ; History allergic reaction attribute compound chemically relate lapatinib ( quinazolines ) , capecitabine , fluorouracil excipients ; Concomitant use CYP3A4 inhibitor inducer ; Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel ; History immediate delay hypersensitivity reaction gadolinium contrast agent , contraindication gadolinium contrast know contraindication MRI ; Concurrent disease condition would make subject inappropriate study participation serious medical psychiatric disorder would interfere patient 's safety compliance study procedure ; acute currently active/requiring antiviral therapy hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease ) ; Any ongoing toxicity prior anti cancer therapy except alopecia ; Active cardiac disease ; Uncontrolled infection ; History malignancy , unless curatively treat evidence disease least 5 year , subject adequately treat DCIS LCIS , adequately treat nonmelanoma skin cancer curatively treat insitu cancer cervix eligible ; Used investigational drug within 30 day 5 halflives , whichever longer , precede first dose protocol treatment ; Pregnant lactating female .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ErbB2</keyword>
	<keyword>HERCEPTIN</keyword>
	<keyword>XELODA</keyword>
	<keyword>ErbB1</keyword>
	<keyword>TYKERB</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>breast cancer</keyword>
	<keyword>capecitabine</keyword>
	<keyword>lapatinib</keyword>
	<keyword>brain metastasis</keyword>
	<keyword>HER2 positive</keyword>
	<keyword>TYVERB</keyword>
</DOC>